Medtronic plc, a global leader in healthcare technology, today announced that Linnea Burman will succeed Dan Volz as SVP & president, Neurovascular business, part of the Neuroscience portfolio. In her new capacity, Burman will be responsible for portfolio strategy, product development, commercial execution and the overall financial performance of the Medtronic global business focused on stroke treatment. Burman will report to Brett Wall, EVP & president, Neuroscience Portfolio. Dan Volz will be stepping into a new role as SVP, Global Commercial Transformation, Medtronic. In this newly established role, Volz will lead the company-wide effort to modernize and transform commercial strategies and go-to-market approaches.

“Linnea is a strategic and visionary leader who maintains a customer-first mindset while building and developing high-performing teams,” said Wall. “Her strong record of success, deep MedTech industry knowledge, and previous experience in stroke demonstrate her business acumen and underscore the commitment to making a meaningful impact on patient outcomes. I have the utmost confidence the Neurovascular business will continue to thrive under her leadership.”

Burman is a transformational leader with more than 20 years of experience managing high-achieving global teams. Prior to her promotion to Neurovascular, Burman served as VP & GM of Enabling Technologies, within the Medtronic Cranial and Spinal Technologies (CST) business. She was integral to establishing CST, driving commercial growth strategies, innovative solutions, and a culture of collaboration.  

Burman has held many leadership positions throughout her tenure at Medtronic. Through the drug delivery business, Linnea played a pivotal role in elevating market development for a post-stroke spasticity indication. Linnea fostered close relationships with renowned stroke neurologists, influential stroke associations, and dedicated patient advocacy groups.

“I'm continually inspired by Medtronic’s dedication to innovation and honored to step into my new role in the Neurovascular business that has transformed the stroke treatment landscape unlike any other MedTech firm," said Burman. “I look forward to working with my new team to build on our proven track record of advancing stroke care practices, fostering new partnerships within the neurovascular community, and developing effective therapies grounded in compelling clinical evidence.”

In addition to her business responsibilities, Burman is actively involved in leading inclusive and supportive professional networks. Burman is passionate about women in leadership positions. She serves as an executive chair for the ASPIRE network, which champions the growth, development, and success of women field employees at Medtronic and is engaged in the Medtronic Women’s Network (MWN) at Medtronic. While at CST, Burman founded the ET Enablers, a global employee group dedicated to enhancing two-way communication and collaboration.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Kelli Lynch
Public Relations
+1-203-500-3328

Ryan Weispfenning
Investor Relations
+1-763-505-4626